Format

Send to

Choose Destination
Aging (Albany NY). 2012 Oct;4(10):709-14.

Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice.

Author information

1
Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

Abstract

TOR (Target of Rapamycin) pathway accelerates cellular and organismal aging. Similar to rapamycin, p53 can inhibit the mTOR pathway in some mammalian cells. Mice lacking one copy of p53 (p53+/- mice) have an increased cancer incidence and a shorter lifespan. We hypothesize that rapamycin can delay cancer in heterozygous p53+/- mice. Here we show that rapamycin (given in a drinking water) extended the mean lifespan of p53+/- mice by 10% and when treatment started early in life (at the age less than 5 months) by 28%. In addition, rapamycin decreased the incidence of spontaneous tumors. This observation may have applications in management of Li-Fraumeni syndrome patients characterized by heterozygous mutations in the p53 gene.

PMID:
23123616
PMCID:
PMC3517941
DOI:
10.18632/aging.100498
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center